Skip to content

Study · Animal study (in vivo) · rat · 2007

5 results

Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.

Dobric I, Drvis P, Petrovic I, Shejbal D, Brcic L, Blagaic AB, Batelja L, Sever M, Kokic N, Tonkic A, Zoricic I, Mise S and 10 more

Show all authors

Staresinic M, Radic B, Jakir A, Babel J, Ilic S, Vuksic T, Jelic I, Anic T, Seiwerth S, Sikiric P

Journal of pharmacological sciences24 Apr 2007Cited by 23 (Europe PMC)

PMID17452811 (opens in a new tab)DOI10.1254/jphs.fp0061322 (opens in a new tab)PepBankPUB-17452811
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis, BPC‑157 alleviated esophagitis, macroscopically and microscopically.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 eased the inflammation of the esophagus.

    Peptide
    BPC-157
    Outcome
    DecreaseEsophagitis severity
    Study

    ratn: not reported in source

    Pyloric-sphincter tube esophagitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg, 10 ng/kg intraperitoneally; 0.16 microg/ml, 0.16 ng/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O).
    1 context sentence
    Summary · context
    Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis and constantly lowered sphincter pressure, BPC‑157 alleviated the pressure deficit in the pyloric sphincter.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 helped restore the low pressure in the stomach outlet muscle.

    Peptide
    BPC-157
    Outcome
    IncreasePyloric sphincter pressure in esophagitis
    Study

    ratn: not reported in source

    Pyloric-sphincter tube esophagitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg, 10 ng/kg intraperitoneally; 0.16 microg/ml, 0.16 ng/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O).
    1 context sentence
    Summary · context
    Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis and constantly lowered sphincter pressure, BPC‑157 alleviated the pressure deficit in the lower esophageal sphincter.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 helped restore the low pressure in the muscle at the lower end of the esophagus.

    Peptide
    BPC-157
    Outcome
    IncreaseLower esophageal sphincter pressure in esophagitis
    Study

    ratn: not reported in source

    Pyloric-sphincter tube esophagitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg, 10 ng/kg intraperitoneally; 0.16 microg/ml, 0.16 ng/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O).
    1 context sentence
    Summary · context
    Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats, BPC‑157 increased lower esophageal sphincter pressure.

    In plain wordsIn healthy rats, BPC‑157 raised the pressure in the muscle at the lower end of the esophagus.

    Peptide
    BPC-157
    Outcome
    IncreaseLower esophageal sphincter pressure in normal rats
    Study

    ratn: not reported in source

    Normal rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure.
    1 context sentence
    Summary · context
    Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats, BPC‑157 decreased pyloric sphincter pressure.

    In plain wordsIn healthy rats, BPC‑157 lowered the pressure in the stomach outlet muscle.

    Peptide
    BPC-157
    Outcome
    DecreasePyloric sphincter pressure in normal rats
    Study

    ratn: not reported in source

    Normal rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure.
    1 context sentence
    Summary · context
    Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.